1. Home
  2. MED vs MOLN Comparison

MED vs MOLN Comparison

Compare MED & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$12.52

Market Cap

120.6M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.00

Market Cap

144.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MED
MOLN
Founded
1980
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
120.6M
144.0M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
MED
MOLN
Price
$12.52
$4.00
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$12.00
$8.38
AVG Volume (30 Days)
191.1K
1.8K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$934,842,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.22
$3.41
52 Week High
$15.37
$5.36

Technical Indicators

Market Signals
Indicator
MED
MOLN
Relative Strength Index (RSI) 67.59 40.95
Support Level $9.91 $3.94
Resistance Level $14.41 $4.54
Average True Range (ATR) 0.63 0.08
MACD 0.12 -0.03
Stochastic Oscillator 75.06 15.25

Price Performance

Historical Comparison
MED
MOLN

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: